Literatur
-
1
Abbink E J, Pickkers P, Jansen von Rosendaal A, Luttermann J A, Tack C J, Russel F GM. et al .
Vascular effects of glibenclamide vs. glimeperide and metformin in type 2 diabetic patients.
Diabetic Med.
2002;
19
136-143
-
2
Aronow W S, Ahn C.
Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone.
Am J Cardiol.
2001;
88
556-557
-
3
Bijlstra P J, Lutterman J A, Russel F GM, Thien T, Smits P.
Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Diabetologia.
1996;
39
1083-1090
-
4
Brady P A, Al-Suwaidi J, Kopeckiy S L, Terzic A.
Sulfonylurea and mortality in diabetic patients with myocardial infarction.
Circulation.
1998;
97
709-710
-
5
Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet.
2002;
359
2072-2077
-
6
Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
J Am Med Ass.
2003;
290
486-494
-
7
Choi D, Kim S K, Ko Y G, Ahn C W, Jang Y, Lim S K. et al .
Preventive effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
Diabetes Care.
2004;
27
2654-2660
-
8
Cleveland J C, Meldrum D R, Cain B S, Banerjee A, Harken A H.
Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: Two paradoxes revisited.
Circulation.
1997;
96
29-32
-
9
Davis T ME, Parsons R W, Broadhurst R J, Hobbs M ST, Jamrozik K.
Arrhythmias and mortality after myocardial infarction in diabetic patients.
Diabetes Care.
1998;
21
637-640
-
10
DeFronzo R, Goodman A M. and the multicenter metformin study group .
Effficacy of metformin in patients with non-insulin-dependent diabetes mellitus.
N Engl J Med.
1995;
333
541-549
-
11
DeFronzo R A.
Pharmacologic therapy for type 2 diabetes mellitus.
Ann Intern Med.
1999;
131
281-303
-
12
Fisman E Z, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A. et al .
Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.
Clin Cardiol.
2001;
24
151-158
-
13
Garratt K N, Brady P A, Hassinger N L, Grill D E, Terzic A, Holmes D R.
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
J Am Coll Cardiol.
1999;
33
119-124
-
14
Geisen K, Végh A, Krause E, Papp J G.
Cardiovascular effects of conventional sulfonyl-ureas and glimeperide.
Horm Metab Res.
1996;
28
496-507
-
15
Gribble F M, Tucker S T, Seino S, Ashcroft F M.
Tissue specificity of sulfonylureas. Studies on cloned cardiac and ß-cell KATP channels.
Diabetes.
1998;
47
1412-1418
-
16
Haffner S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med.
1998;
339
229-234
-
17
Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L. et al .
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study.
Lancet.
2002;
359
2140-2144
-
18
Halkin A, Roth A, Jonas M, Behar S.
Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.
J Thrombosis Thrombolysis.
2001;
12
177-184
-
19
Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Eur Heart J.
2004;
25
10-06
-
20
Hu S, Wang S, Dunning B E.
Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell KATP channels.
J Pharmacol Exp Ther.
1999;
291
1372-1379
-
21
Johnson J A, Majumdar S R, Simpson S H, Toth E L.
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Diabetes Care.
2002;
25
2244-2248
-
22
Jollis J G, Simpson R J, Cascio W E, Chowdhury M K, Crouse J R, Smith S C.
Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction.
Am Heart J.
1999;
I 38
376-380
-
23
Klamann A, Sarfert P, Schulte G, Launhardt V, Schmiegel W, Nauck M A.
Myocardial infarction in diabetic versus non-diabetic subjects. Relation of survival and infarct size following therapy with sulfonylureas (glibenclamide).
Eur Heart J.
2000;
21
220-229
-
24
Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker K H. et al .
Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
Eur Heart J.
1998;
20
439-446
-
25
Lawrence C L, Proks P, Rodrigo G C, Hayabuchi Y, Standen N B, Ashcroft F M.
Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not in rat heart or arterial smooth muscle cells.
Diabetologia.
2001;
44
1019-1025
-
26
Lee T M, Chou T F.
Impairment of myocardial protection in type 2 diabetic patients.
J Clin Endocrinol Metab.
2003;
88
531-537
-
27
Leibowitz G, Cerasi E.
Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?.
Diabetologia.
1996;
39
503-514
-
28
Luft F C.
Lactic acidosis update for critical care clinicians.
J Am Soc Nephrol.
2001;
12
(Suppl 17)
15-19
-
29
Mannucci E, Monami M, Masotti G, Marchionni N.
All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.
Diabetes Metab Res Rev.
2004;
20
44-47
-
30
Matthaei S, Stumvoll M, Kellerer M, Häring H U.
Pathophysiology and pharmacological treatment of insulin resistance.
Endocrine Rev.
2000;
21
585-618
-
31
Meier J J, Deifuss S, Klamann A, Schmiegel W, Nauck M A.
Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The Langendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
Exp Clin Endocrinol Diabetes.
2003;
111
344-350
-
32
Meinert C L, Knatterud G L, Prout T E, Klimt C R. for the UGDP study group .
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes.
Diabetes.
1970;
19
789-830
-
33
Mocanu M M, Maddock H L, Baxter G F, Lawrence C L, Standen N B, Yellon D M.
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
Circulation.
2001;
103
3111-3116
-
34
Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A, Tisell A. et al .
Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.
Diabetologia.
2000;
43
558-560
-
35
Proks P, Reimann F, Green N, Gribble F M, Ashcroft F M.
Sulfonylurea stimulation of in-sulin secretion.
Diabetes.
2002;
51
(Suppl 3)
S 368-376
-
36
Riddle M C, Rosenstock J, Gerich J.
The treat-to-target trial: randomized addition of glar-gine or human NPH insulin to oral therapy of type 2 diabetic patients.
Diabetes Care.
2003;
26
3080-3086
-
37
Rytter L, Troelsen S, Beck-Nielsen H.
Prevalence and mortality of acute myocardial infarction in patients with diabetes.
Diabetes Care.
1985;
8
230-234
-
38
Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, Negut C, Palisi M, Bagolin E. et al .
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.
Diabetes.
2002;
51
808-812
-
39
Soler N G, Pentecost B L, Bennett M A, FitzGerald M G, Lamb P, Malins J M.
Coronary care for myocardial infarction in diabetics.
Lancet.
1974;
1
475-477
-
40
Spallarossa P, Schiavo M, Rossettin P, Cordone S, Olivotti L, Cordera R. et al .
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Diabetes Care.
2001;
24
738-742
-
41
Stratton I M, Adler A I, Neil H A, Matthews D R, Manley S E, Cull C A. et al .
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
Br Med J.
2000;
321
405-412
-
42
Tatsumi T, Matoba S, Kobara M, Keira N, Kawahara A, Tsuruyama K. et al .
Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts.
J Am Coll Cardiol.
1998;
31
707-715
-
43
Thornton J D, Thornton C S, Sterling D L, Downey J M.
Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts.
Circulation Res.
1993;
72
44-49
-
44
Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A. et al RP> .
Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.
Circulation.
1994;
90
700-705
-
45
Tuomilehto J, Lindstrom J, Eriksson J G, Valle T T, Hamalainen H, Ilanne-Parikka P. et al .
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with im-paired glucose tolerance.
N Engl J Med.
2001;
344
1343-1350
-
46
UK prospective diabetes study (UKPDS) group .
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet.
1998;
352
854-865
-
47
UK prospective diabetes study (UKPDS) group .
Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998;
352
837-853
-
48
UK prospective diabetes study group .
UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes.
Diabetes Care.
1998;
21
87-92
-
49
Ulvenstam G, Aberg A, Bergstrand R, Johansson S, Pennert K, Vedin A. et al .
Long-term prognosis after myocardial infarction in men with diabetes.
Diabetes.
1985;
34
787-792
-
50
Vaur L, Danchin N, Hanania G, Cambou J P, Lablanche J M, Blanchard D. et al .
Management and short-term outcome in diabetic patients hospitalized for acute myocardial infarction: Results from a nationwide French survey.
Diabetes Metab.
2003;
29
242-249
-
51
Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M.
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus.
Ann Intern Med.
1999;
130
389-396
-
52
Yki-Järvinen H.
Thiazolidindiones.
N Engl J Med.
2004;
351
1106-1118
Prof. Dr. med. Michael A. Nauck
Diabeteszentrum Bad Lauterberg
Kirchberg 21
37431 Bad Lauterberg im Harz
Phone: 05524/81218
Fax: 05524/81398
Email: M.Nauck@Diabeteszentrum.de
